Broken String

Broken String Biosciences is a genomics company with the goal of developing safer cell and gene therapies by assessing the stability of the genome. The Company is building a technology platform pipeline that will drive the development of cell and gene therapies that are safer by design. Its core technology, INDUCE-seq™, is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and to evaluate the associated genetic risks.

  • Founded by Felix Dobbs, PhD, Prof. Simon Reed, Patrick van Eijk, PhD & Simon Kerr in 2020
  • Initial Investment in September 2021

Felix Dobbs, PhD

Latest news


DvH Ventures invests seven-figure sum in Broken String Biosciences


Let’s talk about it.

Submit your pitch deck here and join our newsletter to receive the latest updates and news about Dieter von Holtzbrinck Ventures.

start your pitch
Dieter von Holtzbrinck Ventures GmbH
Phone+49 221 933 161 0
connect with us on